Duygu İnAn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Duygu İnAn has a total of 169 co-authors. Here are the top co-authors by number of shared publications:
- Ayşe İrem Demirtola
University of Health Sciences Ankara City Hospital - Cardiology Department
9 shared publications - Duygu Genç Albayrak
Department of Cardiology, Basaksehir Cam and Sakura City Hospital, Istanbul 34480, Türkiye
5 shared publications - Alev Kılıçgedik
Department of Cardiology, Başakşehir Çam and Sakura City Hospital, İstanbul, Türkiye
4 shared publications - Anar Mammadli
Ankara Univ, Fac Med, Dept Cardiol, Ankara, Turkey
4 shared publications - Ahmet Guler
Department of Cardiology, Istanbul Basaksehir Cam and Sakura City Hospital, Istanbul 34480, Türkiye
3 shared publications - Aslan Erdoğan
Cardiology Department Basaksehir Cam Sakura City Hospital G‐434 Cd. Istanbul Türkiye
3 shared publications
Latest Publications
- 19 November 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Admission C‐Reactive Protein–Albumin–Lymphocyte Index and Risk Stratification for Contrast‐Associated Acute Kidney Injury in ST‐Segment Elevation Myocardial Infarction: Comparison With the Systemic Immune‐Inflammation Index
Background: Many blood‐based inflammatory and nutritional indices have been linked to contrast‐associated acute kidney injury (CA‐AKI) after primary percutaneous coronary intervention (PCI) for ST‐segment elevation myocardial infarction (STEMI), but they are rarely compared with one another or tested for what they add to existing risk models. The C‐reactive protein–albumin–lymphocyte (CALLY) index and the systemic immune‐inflammation index (SII) both come from routine admission blood tests, yet no study has compared them directly for CA‐AKI or asked whether CALLY adds anything to a standard clinical model. Aims: We tested whether CALLY predicts CA‐AKI independently of SII in STEMI, and whether it improves reclassification and net benefit on top of a full clinical model. Methods: In this retrospective cohort study, we reviewed 1561 consecutive STEMI patients treated with primary PCI between 2021 and 2025. CA‐AKI was defined by the KDIGO 48‐h criterion (creatinine rise ≥ 0.3 mg/dL), with creatinine measured daily in every patient. CALLY and ln(SII) were added, alone and together, to a prespecified clinical risk model. Models were compared with the DeLong test, continuous NRI, IDI, and decision‐curve analysis. Results: CA‐AKI developed in 317 patients (20.3%). CALLY discriminated CA‐AKI better than ln(SII) (AUC 0.632 vs. 0.559; DeLong p = 0.0003). When both were entered together, CALLY stayed independent (OR 0.872, 95% CI 0.783–0.970; p = 0.012), but ln(SII) did not ( p = 0.145), even though SII was independent on its own. Adding CALLY produced only a small change in the C‐statistic (0.752–0.762; DeLong non‐significant), yet it improved reclassification (IDI 0.007, p = 0.003; NRI 0.166, p = 0.005) and net benefit, and calibration remained adequate (Hosmer–Lemeshow p ≥ 0.249). Conclusion: In STEMI patients undergoing primary PCI, a low CALLY index was independently associated with CA‐AKI and improved risk reclassification when added to a clinical model, whereas SII was not independent once CALLY was included. This is the first comparison of CALLY and SII for CA‐AKI, and the first assessment of CALLY for CA‐AKI in STEMI.
- 19 November 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Admission C‐Reactive Protein–Albumin–Lymphocyte Index and Risk Stratification for Contrast‐Associated Acute Kidney Injury in ST‐Segment Elevation Myocardial Infarction: Comparison With the Systemic Immune‐Inflammation Index
Background: Many blood‐based inflammatory and nutritional indices have been linked to contrast‐associated acute kidney injury (CA‐AKI) after primary percutaneous coronary intervention (PCI) for ST‐segment elevation myocardial infarction (STEMI), but they are rarely compared with one another or tested for what they add to existing risk models. The C‐reactive protein–albumin–lymphocyte (CALLY) index and the systemic immune‐inflammation index (SII) both come from routine admission blood tests, yet no study has compared them directly for CA‐AKI or asked whether CALLY adds anything to a standard clinical model. Aims: We tested whether CALLY predicts CA‐AKI independently of SII in STEMI, and whether it improves reclassification and net benefit on top of a full clinical model. Methods: In this retrospective cohort study, we reviewed 1561 consecutive STEMI patients treated with primary PCI between 2021 and 2025. CA‐AKI was defined by the KDIGO 48‐h criterion (creatinine rise ≥ 0.3 mg/dL), with creatinine measured daily in every patient. CALLY and ln(SII) were added, alone and together, to a prespecified clinical risk model. Models were compared with the DeLong test, continuous NRI, IDI, and decision‐curve analysis. Results: CA‐AKI developed in 317 patients (20.3%). CALLY discriminated CA‐AKI better than ln(SII) (AUC 0.632 vs. 0.559; DeLong p = 0.0003). When both were entered together, CALLY stayed independent (OR 0.872, 95% CI 0.783–0.970; p = 0.012), but ln(SII) did not ( p = 0.145), even though SII was independent on its own. Adding CALLY produced only a small change in the C‐statistic (0.752–0.762; DeLong non‐significant), yet it improved reclassification (IDI 0.007, p = 0.003; NRI 0.166, p = 0.005) and net benefit, and calibration remained adequate (Hosmer–Lemeshow p ≥ 0.249). Conclusion: In STEMI patients undergoing primary PCI, a low CALLY index was independently associated with CA‐AKI and improved risk reclassification when added to a clinical model, whereas SII was not independent once CALLY was included. This is the first comparison of CALLY and SII for CA‐AKI, and the first assessment of CALLY for CA‐AKI in STEMI.
- 5 November 2026
- Published by Elsevier in Journal of Electrocardiology
- Vol. 99
Swirling vectors: The myocardial substrate of the precordial swirl pattern in anterior myocardial infarction
- 5 November 2026
- Published by Elsevier in Journal of Electrocardiology
- Vol. 99
Swirling vectors: The myocardial substrate of the precordial swirl pattern in anterior myocardial infarction
- Open Access
- 4 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8594
Association of FIB-4 and APRI with Contrast-Associated Acute Kidney Injury in Patients with Non-ST-Segment Elevation Myocardial Infarction Undergoing Coronary Angiography
Background/Objectives: In patients with non-ST-segment elevation myocardial infarction (NSTEMI), contrast-associated acute kidney injury (CA-AKI) is a clinically important complication of coronary angiography. Whether the Fibrosis-4 (FIB-4) index and aspartate aminotransferase-to-platelet ratio index (APRI) relate to CA-AKI in this setting is unclear. We compared the associations of both indices with CA-AKI. Methods: We retrospectively analyzed 771 patients with NSTEMI who underwent coronary angiography from May 2020 to May 2025. CA-AKI was identified from changes in serum creatinine 48–72 h after contrast administration. Both indices were derived from admission laboratory values. Associations were evaluated using separate multivariable logistic regression models. Discrimination was compared using the paired DeLong test, and the incremental performance of FIB-4 beyond the Mehran score was explored. Results: Overall, 97 patients (12.6%) developed CA-AKI. In the primary adjusted model, FIB-4 was associated with CA-AKI (odds ratio 1.19, 95% confidence interval 1.04–1.36; p = 0.013), but APRI was not. FIB-4 showed modest discrimination but a significantly higher area under the receiver operating characteristic curve (AUC) than APRI (0.614 versus 0.535; DeLong p < 0.001). Adding FIB-4 to the Mehran score improved model fit (likelihood-ratio p = 0.009), but the increase in AUC from 0.646 to 0.666 was not statistically significant (DeLong p = 0.100). Sensitivity analyses showed that the association varied with covariate adjustment. Conclusions: FIB-4 was associated with CA-AKI in the primary adjusted model and showed higher discrimination than APRI. These findings support further investigation of FIB-4 as a potential adjunct to renal risk assessment, although its modest discrimination and uncertain incremental clinical value require independent validation.
- 4 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8594
Open AccessAssociation of FIB-4 and APRI with Contrast-Associated Acute Kidney Injury in Patients with Non-ST-Segment Elevation Myocardial Infarction Undergoing Coronary Angiography
Background/Objectives: In patients with non-ST-segment elevation myocardial infarction (NSTEMI), contrast-associated acute kidney injury (CA-AKI) is a clinically important complication of coronary angiography. Whether the Fibrosis-4 (FIB-4) index and aspartate aminotransferase-to-platelet ratio index (APRI) relate to CA-AKI in this setting is unclear. We compared the associations of both indices with CA-AKI. Methods: We retrospectively analyzed 771 patients with NSTEMI who underwent coronary angiography from May 2020 to May 2025. CA-AKI was identified from changes in serum creatinine 48–72 h after contrast administration. Both indices were derived from admission laboratory values. Associations were evaluated using separate multivariable logistic regression models. Discrimination was compared using the paired DeLong test, and the incremental performance of FIB-4 beyond the Mehran score was explored. Results: Overall, 97 patients (12.6%) developed CA-AKI. In the primary adjusted model, FIB-4 was associated with CA-AKI (odds ratio 1.19, 95% confidence interval 1.04–1.36; p = 0.013), but APRI was not. FIB-4 showed modest discrimination but a significantly higher area under the receiver operating characteristic curve (AUC) than APRI (0.614 versus 0.535; DeLong p < 0.001). Adding FIB-4 to the Mehran score improved model fit (likelihood-ratio p = 0.009), but the increase in AUC from 0.646 to 0.666 was not statistically significant (DeLong p = 0.100). Sensitivity analyses showed that the association varied with covariate adjustment. Conclusions: FIB-4 was associated with CA-AKI in the primary adjusted model and showed higher discrimination than APRI. These findings support further investigation of FIB-4 as a potential adjunct to renal risk assessment, although its modest discrimination and uncertain incremental clinical value require independent validation.
- 20 October 2026
- Published by Elsevier in Journal of Electrocardiology
- Vol. 99, 154479
Pathological Q waves in anterior myocardial infarction: A marker of infarct extent rather than location
- 20 October 2026
- Published by Elsevier in Journal of Electrocardiology
- Vol. 99, 154479
Pathological Q waves in anterior myocardial infarction: A marker of infarct extent rather than location
- Open Access
- 8 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7760
Contemporary Clinical Spectrum and Factors Associated with Mortality in Infective Endocarditis: A Multicenter Cohort Study (COSMO-IE)
Background: Despite continuous advancements in diagnostic imaging and targeted antimicrobial protocols for infective endocarditis (IE), global epidemiological data show that both disease burden and incidence continue to rise. This study aimed to evaluate real-world diagnostic and treatment approaches in accordance with the 2023 European Society of Cardiology (ESC) IE Guidelines and to identify independent predictors of mortality in a contemporary patient cohort. Methods: This multicenter, retrospective cohort study analyzed data from 470 consecutive adult patients diagnosed with IE across 27 academic reference centers between 1 September 2023 and 1 June 2025. Patients were managed and adjudicated according to the 2023 ESC diagnostic criteria. Demographic data, clinical characteristics, microbiological profiles, imaging findings, empirical antibiotic therapy patterns, and clinical outcomes were analyzed. Independent predictors of mortality were determined using multivariable Cox proportional hazards regression models. Results: The mean age of the overall study population was 58.08 ± 16.81 years, with a male predominance (60.6%, n = 285). Staphylococcus aureus was the most frequently isolated pathogen (27.9%), with a high proportion of methicillin resistance (38.9%). Hospital-acquired IE was identified in 41.1% of cases. Surgical treatment was performed in 40.6% (n = 191) of the cohort. The 28-day mortality rate was 11.9%, and the overall mortality during follow-up reached 26.4%. Multivariable Cox regression analysis identified hospital-acquired IE (HR = 2.247; 95% CI: 1.216–4.167; p = 0.010) and the presence of major clinical complications (HR = 4.207; 95% CI: 1.556–11.378; p = 0.005) as the strongest independent predictors of mortality. Conclusions: Contemporary infective endocarditis is a highly complex and fatal disease characterized by a prominent healthcare-associated burden and a predominant staphylococcal etiology. The occurrence of major clinical complications and hospital-acquired infections were the primary independent predictors of mortality.
- 8 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7760
Open AccessContemporary Clinical Spectrum and Factors Associated with Mortality in Infective Endocarditis: A Multicenter Cohort Study (COSMO-IE)
Background: Despite continuous advancements in diagnostic imaging and targeted antimicrobial protocols for infective endocarditis (IE), global epidemiological data show that both disease burden and incidence continue to rise. This study aimed to evaluate real-world diagnostic and treatment approaches in accordance with the 2023 European Society of Cardiology (ESC) IE Guidelines and to identify independent predictors of mortality in a contemporary patient cohort. Methods: This multicenter, retrospective cohort study analyzed data from 470 consecutive adult patients diagnosed with IE across 27 academic reference centers between 1 September 2023 and 1 June 2025. Patients were managed and adjudicated according to the 2023 ESC diagnostic criteria. Demographic data, clinical characteristics, microbiological profiles, imaging findings, empirical antibiotic therapy patterns, and clinical outcomes were analyzed. Independent predictors of mortality were determined using multivariable Cox proportional hazards regression models. Results: The mean age of the overall study population was 58.08 ± 16.81 years, with a male predominance (60.6%, n = 285). Staphylococcus aureus was the most frequently isolated pathogen (27.9%), with a high proportion of methicillin resistance (38.9%). Hospital-acquired IE was identified in 41.1% of cases. Surgical treatment was performed in 40.6% (n = 191) of the cohort. The 28-day mortality rate was 11.9%, and the overall mortality during follow-up reached 26.4%. Multivariable Cox regression analysis identified hospital-acquired IE (HR = 2.247; 95% CI: 1.216–4.167; p = 0.010) and the presence of major clinical complications (HR = 4.207; 95% CI: 1.556–11.378; p = 0.005) as the strongest independent predictors of mortality. Conclusions: Contemporary infective endocarditis is a highly complex and fatal disease characterized by a prominent healthcare-associated burden and a predominant staphylococcal etiology. The occurrence of major clinical complications and hospital-acquired infections were the primary independent predictors of mortality.
- Open Access
- 16 July 2026
- Published by Anatolian Current Medical Journal in Anatolian Current Medical Journal
- Vol. 8 (4) , 668-674
Prognostic value of SCORE2 and SCORE2-OP in patients with severe aortic stenosis undergoing transcatheter or surgical aortic valve replacement
Aims: Despite advances in valve intervention strategies, mortality in patients with severe aortic stenosis remains considerable. The present study investigated whether age-appropriate SCORE2 risk classification provides prognostic information in patients with severe AS undergoing either transcatheter or surgical aortic valve replacement.Methods: This retrospective single-center study included 168 consecutive patients with severe AS who underwent surgical aortic valve replacement (SAVR) or transcatheter aortic valve implantation (TAVI). Cardiovascular risk was estimated using age-appropriate SCORE2 algorithms (SCORE2 for patients aged
- 16 July 2026
- Published by Anatolian Current Medical Journal in Anatolian Current Medical Journal
- Vol. 8 (4) , 668-674
Open AccessPrognostic value of SCORE2 and SCORE2-OP in patients with severe aortic stenosis undergoing transcatheter or surgical aortic valve replacement
Aims: Despite advances in valve intervention strategies, mortality in patients with severe aortic stenosis remains considerable. The present study investigated whether age-appropriate SCORE2 risk classification provides prognostic information in patients with severe AS undergoing either transcatheter or surgical aortic valve replacement.Methods: This retrospective single-center study included 168 consecutive patients with severe AS who underwent surgical aortic valve replacement (SAVR) or transcatheter aortic valve implantation (TAVI). Cardiovascular risk was estimated using age-appropriate SCORE2 algorithms (SCORE2 for patients aged
- Open Access
- 21 May 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (5) , e70353
Rationale and Design of the Türkiye Heart Failure (TURK‐HF) Registry
Aims: The Türkiye Heart Failure (TURK‐HF) registry aims to identify the sociodemographic and clinical characteristics, management strategies, and outcomes of patients with heart failure (HF) and to assess the implementation of evidence‐based HF therapies in Türkiye. Methods: The TURK‐HF registry is a national, multicenter, prospective, observational study of unselected patients with HF regardless of ejection fraction. A total of 46 investigators from 38 centers in 22 cities across Türkiye participated in the registry. The study investigators will gain access to the electronic case report form via www.turkhf.com website using their usernames and passwords. The baseline assessment of the patients will include sociodemographic data, primary care access information, frailty assessment, health‐related quality of life questionnaire, HF‐related information, medical history and comorbidities, physical examination findings, electrocardiographic and echocardiographic data, H 2 FPEF score calculation, laboratory results, and medical and device‐based HF therapies. The management strategies and potential complications of patients hospitalized with acute HF will be systematically documented. Follow‐up data will be collected at regular outpatient visits every 6 months with a margin of error of 1 month. The clinical endpoints of the TURK‐HF registry were cardiovascular or all‐cause mortality, HF‐related hospitalizations, clinician‐interpreted outcomes, patient‐reported outcomes, and surrogate endpoints, either alone or in combination. The TURK‐HF registry was registered at ClinicalTrials.gov (ID: NCT06707220). Conclusion: The TURK‐HF registry offers comprehensive and distinctive insights into contemporary HF clinical characteristics, diagnostic methods, treatments, and outcomes. This registry has the potential to influence implementation strategies, clinical research, and public policies across Türkiye.
- 21 May 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (5) , e70353
Open AccessRationale and Design of the Türkiye Heart Failure (TURK‐HF) Registry
Aims: The Türkiye Heart Failure (TURK‐HF) registry aims to identify the sociodemographic and clinical characteristics, management strategies, and outcomes of patients with heart failure (HF) and to assess the implementation of evidence‐based HF therapies in Türkiye. Methods: The TURK‐HF registry is a national, multicenter, prospective, observational study of unselected patients with HF regardless of ejection fraction. A total of 46 investigators from 38 centers in 22 cities across Türkiye participated in the registry. The study investigators will gain access to the electronic case report form via www.turkhf.com website using their usernames and passwords. The baseline assessment of the patients will include sociodemographic data, primary care access information, frailty assessment, health‐related quality of life questionnaire, HF‐related information, medical history and comorbidities, physical examination findings, electrocardiographic and echocardiographic data, H 2 FPEF score calculation, laboratory results, and medical and device‐based HF therapies. The management strategies and potential complications of patients hospitalized with acute HF will be systematically documented. Follow‐up data will be collected at regular outpatient visits every 6 months with a margin of error of 1 month. The clinical endpoints of the TURK‐HF registry were cardiovascular or all‐cause mortality, HF‐related hospitalizations, clinician‐interpreted outcomes, patient‐reported outcomes, and surrogate endpoints, either alone or in combination. The TURK‐HF registry was registered at ClinicalTrials.gov (ID: NCT06707220). Conclusion: The TURK‐HF registry offers comprehensive and distinctive insights into contemporary HF clinical characteristics, diagnostic methods, treatments, and outcomes. This registry has the potential to influence implementation strategies, clinical research, and public policies across Türkiye.
- Open Access
- 1 January 2026
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 30 (5) , 321-332
Phenotypic, Epidemiologic, and Imaging Features of Hypertrophic Cardiomyopathy: A Single-Center Experience
The Anatolian Journal of Cardiology - Peer-reviewed cardiology journal publishing original research, reviews, case reports. Impact Factor 1.5. The Anatolian Journal of Cardiology - Leading international cardiology journal with Impact Factor 1.5. Publishing original research, reviews, and case reports in cardiovascular medicine. Indexed in PubMed, Scopus, and Web of Science.
- 1 January 2026
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 30 (5) , 321-332
Open AccessPhenotypic, Epidemiologic, and Imaging Features of Hypertrophic Cardiomyopathy: A Single-Center Experience
The Anatolian Journal of Cardiology - Peer-reviewed cardiology journal publishing original research, reviews, case reports. Impact Factor 1.5. The Anatolian Journal of Cardiology - Leading international cardiology journal with Impact Factor 1.5. Publishing original research, reviews, and case reports in cardiovascular medicine. Indexed in PubMed, Scopus, and Web of Science.
- 1 September 2025
- Vol. 41 (5) , 672-675
Transseptal Removal of a Destabilized and Displaced Left Atrial Appendage Closure Device; to Touch or Not to Touch!
- 1 September 2025
- Vol. 41 (5) , 672-675
Transseptal Removal of a Destabilized and Displaced Left Atrial Appendage Closure Device; to Touch or Not to Touch!
- Open Access
- 30 July 2025
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 8 (4) , 556-563
Utility of the CHA₂DS₂-VASc score for predicting cerebral embolic events in patients with infective endocarditis
Aims: Cerebral embolic events (CEEs) are among the most serious complications of infective endocarditis (IE), yet risk stratification remains challenging in routine clinical practice. This study aimed to evaluate the utility of the CHA₂DS₂-VASc score in predicting CEEs during the active phase of IE, using a simple and accessible clinical tool. Methods: This retrospective single-center study included 158 patients with definite IE. CEEs were defined as ischemic stroke or transient ischemic attack confirmed by neuroimaging. The association between the CHA₂DS₂-VASc score and CEEs was assessed using logistic regression. Two models were constructed; model 1 (baseline clinical and echocardiographic variables) and model 2 (model 1+CHA₂DS₂-VASc). Model performance was evaluated using AUC, AIC, Nagelkerke R², Brier Score, calibration curve, and decision curve analysis. Results: CEEs occurred in 32 patients (20%). The CHA₂DS₂-VASc score was significantly higher in patients with CEEs (p=0.011) and remained an independent predictor in multivariate analysis (OR 3.00, 95% CI: 1.26-7.18, p=0.013). Incorporating the CHA₂DS₂-VASc score into the predictive model led to a substantial improvement in discrimination, increasing the AUC from 0.686 to 0.732. A threshold score of 2 provided optimal classification, demonstrating favorable sensitivity and specificity for identifying patients at risk of CEEs. Notably, the predictive value of the score remained robust across key subgroups, including those with left-sided IE, prosthetic material, atrial fibrillation, and preserved ejection fraction. Conclusion: The CHA₂DS₂-VASc score is a strong and independent predictor of CEEs in patients with IE. Its integration into clinical assessment may enhance embolic risk stratification, particularly during the active phase of the disease, and support timely decision-making in this high-risk population.
- 30 July 2025
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 8 (4) , 556-563
Open AccessUtility of the CHA₂DS₂-VASc score for predicting cerebral embolic events in patients with infective endocarditis
Aims: Cerebral embolic events (CEEs) are among the most serious complications of infective endocarditis (IE), yet risk stratification remains challenging in routine clinical practice. This study aimed to evaluate the utility of the CHA₂DS₂-VASc score in predicting CEEs during the active phase of IE, using a simple and accessible clinical tool. Methods: This retrospective single-center study included 158 patients with definite IE. CEEs were defined as ischemic stroke or transient ischemic attack confirmed by neuroimaging. The association between the CHA₂DS₂-VASc score and CEEs was assessed using logistic regression. Two models were constructed; model 1 (baseline clinical and echocardiographic variables) and model 2 (model 1+CHA₂DS₂-VASc). Model performance was evaluated using AUC, AIC, Nagelkerke R², Brier Score, calibration curve, and decision curve analysis. Results: CEEs occurred in 32 patients (20%). The CHA₂DS₂-VASc score was significantly higher in patients with CEEs (p=0.011) and remained an independent predictor in multivariate analysis (OR 3.00, 95% CI: 1.26-7.18, p=0.013). Incorporating the CHA₂DS₂-VASc score into the predictive model led to a substantial improvement in discrimination, increasing the AUC from 0.686 to 0.732. A threshold score of 2 provided optimal classification, demonstrating favorable sensitivity and specificity for identifying patients at risk of CEEs. Notably, the predictive value of the score remained robust across key subgroups, including those with left-sided IE, prosthetic material, atrial fibrillation, and preserved ejection fraction. Conclusion: The CHA₂DS₂-VASc score is a strong and independent predictor of CEEs in patients with IE. Its integration into clinical assessment may enhance embolic risk stratification, particularly during the active phase of the disease, and support timely decision-making in this high-risk population.